Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 20/100

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE

Key Takeaway: Skye Bioscience, Inc. is currently facing a class action lawsuit initiated by the DJS Law Group for violations of federal securities laws. The lawsuit alleges that the company misled investors regarding the efficacy of its drug, nimacimab, during the class period from November 4, 2024, to October 3, 2025. Shareholders who purchased shares during this time frame are encouraged to register for potential recovery. The deadline for joining the case is January 16, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • Skye Bioscience is facing a class action lawsuit for securities law violations.
  • The company's drug, nimacimab, reportedly failed to demonstrate previously claimed efficacy.
  • Public statements made by Skye during the class period were found to be false and materially misleading.

Full Press Release Details

LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 4, 2024 to October 3, 2025
DEADLINE: January 16, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Skye’s nimacimab failed to demonstrate the efficacy it had previously claimed. Based on these facts, Skye’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What is the class action lawsuit against Skye Bioscience about?

The lawsuit involves alleged violations of securities laws due to false statements by Skye regarding nimacimab's efficacy.

What is the class period for the Skye lawsuit?

The class period runs from November 4, 2024, to October 3, 2025.

When is the deadline to join the lawsuit against Skye?

Shareholders have until January 16, 2026, to join the lawsuit.

Do I need to be a lead plaintiff to participate?

No, becoming a lead plaintiff is not necessary to be eligible for recovery.

How can I receive updates on the case?

Once registered, shareholders receive updates via portfolio monitoring software.

Last updated: Dec 1, 2025